发布求助
文献互助 智能选刊 最新文献

Future oncology最新文献

筛选
英文 中文
Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors. 黎巴嫩的局部晚期/转移性非小细胞肺癌：关注 ALK 酪氨酸激酶抑制剂。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-11-15 DOI: 10.1080/14796694.2024.2421737
Arafat Tfayli, Hady Ghanem, Fadi Nasr, Hampig Raphael Kourie, Georges El Hachem, Jamil Debs, Sarah Masri, Hazem I Assi, Rosario García Campelo, Joseph Kattan
{"title":"Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors.","authors":"Arafat Tfayli, Hady Ghanem, Fadi Nasr, Hampig Raphael Kourie, Georges El Hachem, Jamil Debs, Sarah Masri, Hazem I Assi, Rosario García Campelo, Joseph Kattan","doi":"10.1080/14796694.2024.2421737","DOIUrl":"10.1080/14796694.2024.2421737","url":null,"abstract":"<p><p>Treatment of non-small-cell lung cancers (NSCLC) has evolved over the last decade. According to studies, the use of targeted therapies has significantly increased the life expectancy of patients. Moreover, ALK-tyrosine kinase inhibitors (ALK-TKIs) have improved clinical outcomes. In Lebanon, translating recommendations into clinical practice remains challenging. A Lebanese expert panel of oncologists was convened to describe the management paradigm and the clinical evidence supporting the optimal use of next-generation TKIs in patients with <i>ALK</i>-rearranged NSCLC and to provide an expert overview of local challenges and recommendations for optimizing the management of advanced NSCLC in Lebanese patients. The experts agreed that these recommendations should be part of a healthcare strategy to be implemented at the national level.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"127-137"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decoding clinical trial jargon: helping people understand how safety and quality of life are assessed in cancer trials. 解读临床试验术语：帮助人们了解在癌症试验中如何评估安全性和生活质量。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-12-02 DOI: 10.1080/14796694.2024.2422808
Jenny Burkholder, Amy Burkholder, Gissoo DeCotiis, Hannah FitzGibbon, Pallav Mehta
{"title":"Decoding clinical trial jargon: helping people understand how safety and quality of life are assessed in cancer trials.","authors":"Jenny Burkholder, Amy Burkholder, Gissoo DeCotiis, Hannah FitzGibbon, Pallav Mehta","doi":"10.1080/14796694.2024.2422808","DOIUrl":"10.1080/14796694.2024.2422808","url":null,"abstract":"<p><p>[Figure: see text].</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"5-10"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. 达拉单抗联合来那度胺、硼替佐米和地塞米松治疗新诊断多发性骨髓瘤患者的GRIFFIN研究最终分析摘要。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-10-25 DOI: 10.1080/14796694.2024.2408909
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Shira Dinner, Katharine S Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson
{"title":"A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.","authors":"Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Shira Dinner, Katharine S Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson","doi":"10.1080/14796694.2024.2408909","DOIUrl":"10.1080/14796694.2024.2408909","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"25-49"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023). 英国晚期高级别上皮性卵巢癌治疗的当前做法：OC-NOW调查（2023年）。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-11-25 DOI: 10.1080/14796694.2024.2424153
Christina Fotopoulou, Rebecca Bowen, Ranjit Manchanda, Agnieszka Michael, Stephen McCormack, Allan Ullmann, Anthony Wesselbaum, Bethany Levick, Rowan Miller
{"title":"Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023).","authors":"Christina Fotopoulou, Rebecca Bowen, Ranjit Manchanda, Agnieszka Michael, Stephen McCormack, Allan Ullmann, Anthony Wesselbaum, Bethany Levick, Rowan Miller","doi":"10.1080/14796694.2024.2424153","DOIUrl":"10.1080/14796694.2024.2424153","url":null,"abstract":"<p><p><b>Aim:</b> To investigate current management of advanced epithelial ovarian cancer (OC) in the UK.<b>Materials & methods:</b> A cross-sectional survey with 55 healthcare professionals involved in the care of OC patients was conducted via telephone/videoconference in March/May 2023.<b>Results:</b> Respondents reported that homologous recombination deficiency (HRD) status and brca mutations were routinely tested before planning maintenance treatment. All respondents agreed that cytoreductive surgery should be considered at first recurrence, and 65% recommended using the Descriptive Evaluation of Preoperative Selection Criteria for Operability in Recurrent Ovarian Cancer (DESKTOP) III criteria to guide secondary cytoreduction. Platinum responders typically receive poly (ADP-ribose) polymerase inhibitor maintenance therapy, regardless of HRD status.<b>Conclusion:</b> Respondents reinforce that most primary OC patients in the UK have known HRD and <i>BRCA</i> mutation status, and the role of secondary cytoreduction is increasingly recognized.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"95-103"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". 多斯他利单抗治疗原发性晚期或复发性子宫内膜癌 "的通俗语言摘要。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-07-11 DOI: 10.2217/fon-2023-0940
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M Landrum, Lars C Hanker, Ashley Stuckey, Ingrid Boere, Michael A Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn McCourt, Francesco Raspagliesi, Mark S Shahin, Sarah E Gill, Bradley J Monk, Joseph Buscema, Thomas J Herzog, Larry J Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L Coleman, Matthew A Powell
{"title":"A Plain Language Summary of \"Dostarlimab for primary advanced or recurrent endometrial cancer\".","authors":"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M Landrum, Lars C Hanker, Ashley Stuckey, Ingrid Boere, Michael A Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn McCourt, Francesco Raspagliesi, Mark S Shahin, Sarah E Gill, Bradley J Monk, Joseph Buscema, Thomas J Herzog, Larry J Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L Coleman, Matthew A Powell","doi":"10.2217/fon-2023-0940","DOIUrl":"10.2217/fon-2023-0940","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"151-168"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer.
IF 3 4区 医学
Future oncology Pub Date : 2024-12-29 DOI: 10.1080/14796694.2024.2447813
Li You, Min Wang, Xuexue Liu, Miao Song, Jiahong Zhou, Jia Feng, Jinbo Liu
{"title":"DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer.","authors":"Li You, Min Wang, Xuexue Liu, Miao Song, Jiahong Zhou, Jia Feng, Jinbo Liu","doi":"10.1080/14796694.2024.2447813","DOIUrl":"https://doi.org/10.1080/14796694.2024.2447813","url":null,"abstract":"<p><p>Breast cancer (BC) is a global women's health concern, with ongoing research to address diagnostic and treatment challenges. Understanding the developmental mechanisms is vital for improved clinical prevention and treatment strategies. Mitochondria, undergo dynamic processes like fission and fusion, regulated by proteins like Dynamic-related protein 1 (DRP1). DRP1 plays a key role in mitochondrial fission, a process associated with BC development. This study aims to explore the impact of DRP1 on BC growth, assessing its potential as a therapeutic target. The findings could contribute to a better understanding of mitochondria-related molecular mechanisms in BC development and guide the identification of clinical drug targets.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2024-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 修正。
IF 3 4区 医学
Future oncology Pub Date : 2024-12-20 DOI: 10.1080/14796694.2024.2445908
{"title":"Correction.","authors":"","doi":"10.1080/14796694.2024.2445908","DOIUrl":"10.1080/14796694.2024.2445908","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1"},"PeriodicalIF":3.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary. 早期与延迟鲁索利替尼治疗骨髓纤维化患者：一个简单的语言总结。
IF 3 4区 医学
Future oncology Pub Date : 2024-12-18 DOI: 10.1080/14796694.2024.2440255
Claire Harrison, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Ruben A Mesa
{"title":"Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.","authors":"Claire Harrison, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Ruben A Mesa","doi":"10.1080/14796694.2024.2440255","DOIUrl":"https://doi.org/10.1080/14796694.2024.2440255","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence? 通俗易懂的摘要：恩扎鲁胺联合或不联合利血平治疗能否改善高危生化复发患者的预后并影响其生活质量？
IF 3 4区 医学
Future oncology Pub Date : 2024-12-12 DOI: 10.1080/14796694.2024.2426425
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Ronald F Tutrone, Balaji Venugopal, Henry H Woo, Miguel Ramirez-Backhaus, Jamal Tarazi, Yiyun Tang, Arijit Ganguli, Gabriel P Haas, Neal D Shore
{"title":"Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?","authors":"Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Ronald F Tutrone, Balaji Venugopal, Henry H Woo, Miguel Ramirez-Backhaus, Jamal Tarazi, Yiyun Tang, Arijit Ganguli, Gabriel P Haas, Neal D Shore","doi":"10.1080/14796694.2024.2426425","DOIUrl":"https://doi.org/10.1080/14796694.2024.2426425","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-14"},"PeriodicalIF":3.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 修正。
IF 3 4区 医学
Future oncology Pub Date : 2024-12-12 DOI: 10.1080/14796694.2024.2441035
{"title":"Correction.","authors":"","doi":"10.1080/14796694.2024.2441035","DOIUrl":"https://doi.org/10.1080/14796694.2024.2441035","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1"},"PeriodicalIF":3.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信